Answers are grounded in this paper and cite their sources.
Review assesses therapies and challenges in treating biliary tract cancer, highlighting the need for improvement.
Biliary tract cancers (BTC) are a rare and aggressive consortium of malignancies, consisting of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma. While most patients present with metastatic disease, a minority of patients with BTC are eligible for curative surgical resection at the time of presentation. However, these patients have poor 5-year overall survival rates and high rates of recurrence, necessitating the improvement of the neoadjuvant and adjuvant treatment of BTC. In this review, we assess the neoadjuvant and adjuvant clinical trials for the treatment of BTC and discuss the challenges and limitations of clinical trials, as well as future directions for the treatment of BTC.
No takes yet. Share an insight, caveat, or question.
Wilbur et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: